Objective:This study aims to synthesize a novel selenium-containing benzo[b]azepine derivative,1-((4-(tert-butyl)phenyl)sulfonyl)-5-phenyl-3-((phenylselanyl)methyl)-2,3-dihydro-1H-benzo[b]azepine,using an electrochemical method,and to preliminarily investigate its potential anti-inflammatory activity and mechanism of action.Methods:We successfully synthesize the target compound by using electrochemical methods and evaluated its cytotoxicity on mouse monocyte/macrophage cell line RAW 264.7 using the CCK-8 assay.An in vitro cellular inflammation model induced by lipopolysaccharide(LPS)is utilized to intervene with different concentrations of the compound.The Griess method is employed to measure the NO content in the cell supernatant,and the levels of TNF-α and IL-6 are determined by ELISA.Additionally,real-time fluorescence quantitative PCR technology is used to detect the expression of TNF-α,IL-1β,and IL-6 mRNA.Results:The target compound is synthesized with a 55%yield through electrochemical methods.Within the concentration range of 1 to 100 μmol/L,the compound shows no significant toxicity to RAW 264.7 cells.The compound exhibited a significant inhibitory effect on NO production,with a half-maximal inhibitory concentration(IC50)of 0.41 μmol/L,and this inhibitory effect is dose-dependent.At the administered concentrations of 0.5 to 2.0 μmol/L,the high-dose group significantly reduced the expression of TNF-α,IL-1β,and IL-6 mRNA in RAW 264.7 cells,with a significant difference compared to the LPS-induced control group(p＜0.01).Conclusion:Electrochemical synthesis is a green and efficient method for the synthesis of benzo[b]azepine derivatives.1-((4-(tert-butyl)phenyl)sulfonyl)-5-phenyl-3-((phenylselanyl)methyl)-2,3-dihydro-1H-benzo[b]azepine demonstrates its potential as an anti-inflammatory agent by inhibiting the release of inflammatory factors such as TNF-α,IL-1β,and IL-6 from RAW 264.7 cells,and may exert its anti-inflammatory effects by regulating the NO pathway,thereby confirming its potential as a promising anti-inflammatory drug candidate.
NETL
NSTL
万方数据
